leisure time -WSS

leisure time

author：comprehensive 2025-09-30 20:34:53 - browse：6155

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Abbott's new stent may help patients with peripheral artery disease

leisure time

WSS

FDA clears Verve to begin U.S. study of gene

Novo Nordisk testing Wegovy against alcohol

STAT Summit: The economic case for universal basic health care

STAT Summit: Meghan O’Rourke on making chronic illness visible

Fertility clinic egg and embryo storage is a disaster

WuXi Biologics beefs up its lobbying operation

focus

leisure time

knowledge

Walensky prepares to leave CDC — and Congress — behind

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Sports medicine is finally prioritizing gender equality

Roivant's CEO is a star, but biotech's black hole persists

Heart attack and stroke risk calculators need revising

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

FDA approval of Sarepta Duchenne genetic therapy gives me hope

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

As demand for Covid shots wanes, Moderna seeks its next success

Supreme Court to hear if Covid misinformation is protected speech

Wikipedia

CVS is willing to dump 10% of its Medicare Advantage members

STAT Readout Newsletter: Biotech news today

Smaller biotechs seek to piggyback on weight loss drug boom

How AI can help patients find reliable information about doctors

Smaller biotechs seek to piggyback on weight loss drug boom

Cassava Sciences’ Alzheimer’s clinical trials should be halted

hotspot

leisure time

hotspot

hotspot